The presentation will cover the nature of Cytokine release Syndrome (CRS) which is the most common side effect of bispecific antibodies.  Explain the mode of action of Bispecific antibodies and how this can result in CRS. Discussing ASTCT Consensus grading to evaluate patients and how CRS is treated in relation to this grading. 
 
With the administration of Bispecifics antibodies there are methods to mitigate CRS and I will discuss these which include step up dosing amongst others and the use of steroids prior to infusion.
 
Examples will be used to demonstrate how CRS is graded in practice and highlight the management required. Data and a case study will also be discussed from my experience of Bispecific antibodies delivery.